A plain language summary of results from the GARNET study of dostarlimab in patients with endometrial cancer

Ana Oaknin; Lucy Gilbert; Anna V. Tinker; Jubilee Brown; Cara Mathews; Joshua Press; Renaud Sabatier; David M. O'Malley; Vanessa Samouelian; Valentina Boni; Linda Duska; Sharad Ghamande; Prafull Ghatage; Rebecca Kristeleit; Charles Leath; Yuping Dong; Jennifer Veneris; Bhavana Pothuri

doi:10.2217/fon-2022-1157

A plain language summary of results from the GARNET study of dostarlimab in patients with endometrial cancer

Ana Oaknin, Lucy Gilbert, Anna V. Tinker, Jubilee Brown, Cara Mathews, Joshua Press, Renaud Sabatier, David M. O'Malley, Vanessa Samouelian, Valentina Boni, Linda Duska, Sharad Ghamande, Prafull Ghatage, Rebecca Kristeleit, Charles Leath, Yuping Dong, Jennifer Veneris, Bhavana Pothuri

Obstetrics and Gynecology

Research output: Contribution to journal › Review article › peer-review

Abstract

What is this summary about? Dostarlimab, also known by the brand name JEMPERLI, is a medicine that can be used to treat certain types of endometrial cancer. GARNET is an ongoing phase 1 clinical study that is testing the safety and side effects of dostarlimab and the best way to administer it to patients. The results presented in this summary are from a time point in the middle of the study. What were the results? The results from the GARNET study published in 2022 showed how well dostarlimab worked for people participating in the study. Dostarlimab was found to reduce the size of tumors in patients with certain types of endometrial cancer. The patients treated with dostarlimab had side effects that could be managed and few severe side effects. What do the results mean? The results of the GARNET study led to dostarlimab being approved to treat patients with certain types of endometrial cancer. For patients with advanced-stage endometrial cancer, or endometrial cancer that has come back after chemotherapy (recurrent), there are few treatment options. The results suggest that dostarlimab may provide long-term benefits for these patients. </sec.

Original language	English (US)
Pages (from-to)	1709-1714
Number of pages	6
Journal	Future Oncology
Volume	19
Issue number	25
DOIs	https://doi.org/10.2217/fon-2022-1157
State	Published - Aug 1 2023

Keywords

Endometrial Cancer
Gynecologic Cancer
Immunotherapy
Plain Language Summary

ASJC Scopus subject areas

Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.2217/fon-2022-1157

Cite this

Oaknin, A., Gilbert, L., Tinker, A. V., Brown, J., Mathews, C., Press, J., Sabatier, R., O'Malley, D. M., Samouelian, V., Boni, V., Duska, L., Ghamande, S., Ghatage, P., Kristeleit, R., Leath, C., Dong, Y., Veneris, J., & Pothuri, B. (2023). A plain language summary of results from the GARNET study of dostarlimab in patients with endometrial cancer. Future Oncology, 19(25), 1709-1714. https://doi.org/10.2217/fon-2022-1157

Oaknin, A, Gilbert, L, Tinker, AV, Brown, J, Mathews, C, Press, J, Sabatier, R, O'Malley, DM, Samouelian, V, Boni, V, Duska, L, Ghamande, S, Ghatage, P, Kristeleit, R, Leath, C, Dong, Y, Veneris, J & Pothuri, B 2023, 'A plain language summary of results from the GARNET study of dostarlimab in patients with endometrial cancer', Future Oncology, vol. 19, no. 25, pp. 1709-1714. https://doi.org/10.2217/fon-2022-1157

@article{2ea4d41a41054d879fc1d77a9ebca19e,

title = "A plain language summary of results from the GARNET study of dostarlimab in patients with endometrial cancer",

abstract = "What is this summary about? Dostarlimab, also known by the brand name JEMPERLI, is a medicine that can be used to treat certain types of endometrial cancer. GARNET is an ongoing phase 1 clinical study that is testing the safety and side effects of dostarlimab and the best way to administer it to patients. The results presented in this summary are from a time point in the middle of the study. What were the results? The results from the GARNET study published in 2022 showed how well dostarlimab worked for people participating in the study. Dostarlimab was found to reduce the size of tumors in patients with certain types of endometrial cancer. The patients treated with dostarlimab had side effects that could be managed and few severe side effects. What do the results mean? The results of the GARNET study led to dostarlimab being approved to treat patients with certain types of endometrial cancer. For patients with advanced-stage endometrial cancer, or endometrial cancer that has come back after chemotherapy (recurrent), there are few treatment options. The results suggest that dostarlimab may provide long-term benefits for these patients. ",

keywords = "Endometrial Cancer, Gynecologic Cancer, Immunotherapy, Plain Language Summary",

author = "Ana Oaknin and Lucy Gilbert and Tinker, {Anna V.} and Jubilee Brown and Cara Mathews and Joshua Press and Renaud Sabatier and O'Malley, {David M.} and Vanessa Samouelian and Valentina Boni and Linda Duska and Sharad Ghamande and Prafull Ghatage and Rebecca Kristeleit and Charles Leath and Yuping Dong and Jennifer Veneris and Bhavana Pothuri",

note = "Publisher Copyright: {\textcopyright} 2023 The Authors.",

year = "2023",

month = aug,

day = "1",

doi = "10.2217/fon-2022-1157",

language = "English (US)",

volume = "19",

pages = "1709--1714",

journal = "Future Oncology",

issn = "1479-6694",

publisher = "Future Medicine Ltd.",

number = "25",

}

TY - JOUR

T1 - A plain language summary of results from the GARNET study of dostarlimab in patients with endometrial cancer

AU - Oaknin, Ana

AU - Gilbert, Lucy

AU - Tinker, Anna V.

AU - Brown, Jubilee

AU - Mathews, Cara

AU - Press, Joshua

AU - Sabatier, Renaud

AU - O'Malley, David M.

AU - Samouelian, Vanessa

AU - Boni, Valentina

AU - Duska, Linda

AU - Ghamande, Sharad

AU - Ghatage, Prafull

AU - Kristeleit, Rebecca

AU - Leath, Charles

AU - Dong, Yuping

AU - Veneris, Jennifer

AU - Pothuri, Bhavana

PY - 2023/8/1

Y1 - 2023/8/1

N2 - What is this summary about? Dostarlimab, also known by the brand name JEMPERLI, is a medicine that can be used to treat certain types of endometrial cancer. GARNET is an ongoing phase 1 clinical study that is testing the safety and side effects of dostarlimab and the best way to administer it to patients. The results presented in this summary are from a time point in the middle of the study. What were the results? The results from the GARNET study published in 2022 showed how well dostarlimab worked for people participating in the study. Dostarlimab was found to reduce the size of tumors in patients with certain types of endometrial cancer. The patients treated with dostarlimab had side effects that could be managed and few severe side effects. What do the results mean? The results of the GARNET study led to dostarlimab being approved to treat patients with certain types of endometrial cancer. For patients with advanced-stage endometrial cancer, or endometrial cancer that has come back after chemotherapy (recurrent), there are few treatment options. The results suggest that dostarlimab may provide long-term benefits for these patients.

AB - What is this summary about? Dostarlimab, also known by the brand name JEMPERLI, is a medicine that can be used to treat certain types of endometrial cancer. GARNET is an ongoing phase 1 clinical study that is testing the safety and side effects of dostarlimab and the best way to administer it to patients. The results presented in this summary are from a time point in the middle of the study. What were the results? The results from the GARNET study published in 2022 showed how well dostarlimab worked for people participating in the study. Dostarlimab was found to reduce the size of tumors in patients with certain types of endometrial cancer. The patients treated with dostarlimab had side effects that could be managed and few severe side effects. What do the results mean? The results of the GARNET study led to dostarlimab being approved to treat patients with certain types of endometrial cancer. For patients with advanced-stage endometrial cancer, or endometrial cancer that has come back after chemotherapy (recurrent), there are few treatment options. The results suggest that dostarlimab may provide long-term benefits for these patients.

KW - Endometrial Cancer

KW - Gynecologic Cancer

KW - Immunotherapy

KW - Plain Language Summary

UR - http://www.scopus.com/inward/record.url?scp=85169847521&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85169847521&partnerID=8YFLogxK

U2 - 10.2217/fon-2022-1157

DO - 10.2217/fon-2022-1157

M3 - Review article

C2 - 37381977

AN - SCOPUS:85169847521

SN - 1479-6694

VL - 19

SP - 1709

EP - 1714

JO - Future Oncology

JF - Future Oncology

IS - 25

ER -

A plain language summary of results from the GARNET study of dostarlimab in patients with endometrial cancer

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this